CORCEPT Therapeutics officer Vieira Roberto Wandenkolk plans to sell 75,295 common shares worth approximately $8,339,418. The transaction gives investors a disclosed seller, broker and share-origin breakdown, including 74,999 shares from a stock-option exercise and 296 from an ESPP transaction.
Key Highlights
- Vieira Roberto Wandenkolk is identified as an officer connected with CORCEPT Therapeutics.
- Stifel Nicolaus & Company Inc. is named in connection with the proposed sale.
- The transaction record includes 74,999 shares from a stock-option exercise dated Feb 1, 2024, and 296 shares from an ESPP transaction dated Sep 1, 2026.
Vieira Roberto Wandenkolk filed to sell 75,295 CORCEPT Therapeutics (NASDAQ: CORT) common shares valued at approximately $8,339,418 ($8.34 million). The filing is dated Sep 2, 2026.
The transaction details link 74,999 common shares to a stock-option exercise dated Feb 1, 2024. The remaining 296 common shares are associated with an employee stock purchase plan transaction dated Sep 1, 2026. Both entries identify the issuer and cash as the consideration. Stifel Nicolaus & Company Inc. is named in connection with the sale and is listed at an address in St. Louis, Missouri 63,102. CORCEPT Therapeutics is listed at 101 Redwood Shores Parkway, Redwood City, California 94,065, with the telephone number 650.688.8803. The record carries a June 17, 2026 signature from James Weimer as Wandenkolk’s authorized representative.
FAQs
Q: How many CORCEPT Therapeutics shares does Roberto Wandenkolk plan to sell?
A: The filing states that Vieira Roberto Wandenkolk filed to sell 75,295 CORCEPT Therapeutics common shares. It reports an approximate value of $8,339,418 for those shares.
Q: What does the CORCEPT Therapeutics filing identify?
A: The filing identifies 75,295 common shares that Vieira Roberto Wandenkolk filed to sell. It also names Stifel Nicolaus & Company Inc. in connection with the filing.
Q: Where did the shares in the CORCEPT Therapeutics sale come from?
A: The transaction includes 74,999 shares from a stock-option exercise dated Feb 1, 2024. Another 296 shares are tied to an ESPP transaction dated Sep 1, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.